1. Home
  2. CBAN vs SGMT Comparison

CBAN vs SGMT Comparison

Compare CBAN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBAN
  • SGMT
  • Stock Information
  • Founded
  • CBAN 1975
  • SGMT 2006
  • Country
  • CBAN United States
  • SGMT United States
  • Employees
  • CBAN N/A
  • SGMT N/A
  • Industry
  • CBAN Major Banks
  • SGMT
  • Sector
  • CBAN Finance
  • SGMT
  • Exchange
  • CBAN Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • CBAN 279.6M
  • SGMT 269.2M
  • IPO Year
  • CBAN 1998
  • SGMT 2023
  • Fundamental
  • Price
  • CBAN $16.60
  • SGMT $8.71
  • Analyst Decision
  • CBAN
  • SGMT Strong Buy
  • Analyst Count
  • CBAN 0
  • SGMT 8
  • Target Price
  • CBAN N/A
  • SGMT $27.25
  • AVG Volume (30 Days)
  • CBAN 59.4K
  • SGMT 722.5K
  • Earning Date
  • CBAN 07-23-2025
  • SGMT 08-13-2025
  • Dividend Yield
  • CBAN 2.78%
  • SGMT N/A
  • EPS Growth
  • CBAN 24.13
  • SGMT N/A
  • EPS
  • CBAN 1.57
  • SGMT N/A
  • Revenue
  • CBAN $118,533,000.00
  • SGMT N/A
  • Revenue This Year
  • CBAN $18.25
  • SGMT N/A
  • Revenue Next Year
  • CBAN $7.59
  • SGMT N/A
  • P/E Ratio
  • CBAN $10.54
  • SGMT N/A
  • Revenue Growth
  • CBAN 8.33
  • SGMT N/A
  • 52 Week Low
  • CBAN $13.43
  • SGMT $1.73
  • 52 Week High
  • CBAN $18.49
  • SGMT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • CBAN 50.83
  • SGMT 55.77
  • Support Level
  • CBAN $15.86
  • SGMT $8.62
  • Resistance Level
  • CBAN $16.94
  • SGMT $10.06
  • Average True Range (ATR)
  • CBAN 0.35
  • SGMT 0.70
  • MACD
  • CBAN 0.01
  • SGMT -0.05
  • Stochastic Oscillator
  • CBAN 60.66
  • SGMT 58.06

About CBAN Colony Bankcorp Inc.

Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: